Drugs / Vanucizumab
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02665416 | Jan 2016 → Oct 2019 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01688206 | Oct 2012 → Dec 2016 | neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02141295 | Jun 2014 → Jul 2016 | colorectal cancer | Hoffmann-La Roche | Terminated | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vanucizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02141295 ↗ |
| Known as | C0u97738ae | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545259 ↗ |
| Known as | RG-7221 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545259 ↗ |
| Known as | RO-5520985 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545259 ↗ |
| Action | Inhibit | “Anti-Ang2 and Anti-VEGF Bi-Specific Monoclonal Antibody” NCT02665416 ↗2“Vascular endothelial growth factor A inhibitor” CHEMBL3545259 ↗ “Angiopoietin-2 inhibitor” CHEMBL3545259 ↗ |
| Modality | Monoclonal antibody | “Anti-Ang2 and Anti-VEGF Bi-Specific Monoclonal Antibody” NCT02665416 ↗ |
| Route | Intravenous | “intravenously every 2 weeks” NCT01688206 ↗ |
| Target | ANGPT2 | “Angiopoietin-2 inhibitor” CHEMBL3545259 ↗ |
| Target | VEGFA | “Vascular endothelial growth factor A inhibitor” CHEMBL3545259 ↗ |